{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:30:28Z","timestamp":1773894628614,"version":"3.50.1"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Distinguishing primary lung squamous cell carcinoma (SCC) from squamous metastases to the lung is a clinical challenge due to histopathologic similarities. Accurate diagnosis is essential to guide treatment decisions.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the utility of an artificial intelligence (AI) approach that includes evaluation of key orthogonal evidence in distinguishing primary lung SCCs from metastatic tumors of other tissue origins.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study used GPSai, a tissue-of-origin AI model run automatically on each sample submitted for molecular profiling, to flag potential misdiagnoses among research-eligible cases submitted as lung SCC. Molecularly profiled cases within the Caris Life Sciences clinicogenomic database from January 1, 2024, to January 31, 2025, were queried. All cases were reviewed by board-certified pathologists.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the rate of misdiagnosis among presumed lung SCCs confirmed by pathologist review and orthogonal evidence, which included clinical history and clinical findings, GATA3 and uroplakin II immunohistochemistry for urothelial carcinoma, UV variant signature for cutaneous SCC, CD5 and CD117 (c-KIT) immunohistochemistry for thymic carcinoma, and human papillomavirus positivity for orogenital SCC (eg, head and neck, cervical).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Through a combination of AI and orthogonal evidence, 123 (3.1%) misdiagnoses were confirmed among 3958 cases submitted as presumed lung SCC (patients misdiagnosed: median [range] age, 71 [39 to &amp;gt;89]; 76.4% male). The cohort included 50 cutaneous SCCs (40.7%), 33 orogenital SCCs (26.8%) (including 25 head and neck [75.8%]), 20 urothelial carcinomas (16.3%), 15 thymic carcinomas (12.2%), 4 NUT carcinomas (3.3%), and 1 prostate SCC (0.8%). Ninety-two of the 123 patients (74.8%) had clinical history or findings consistent with the new diagnosis. Eighty-eight cases (71.5%) had differences in guideline\u2013preferred first-line systemic therapies following the diagnosis change.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cross-sectional study of patients diagnosed with lung SCC, a meaningful number of patients experienced misdiagnosis, which was identified using a multipronged AI-assisted approach. Diagnosis changes prompted by AI and orthogonal evidence may assist clinicians in prognostication and therapy selection.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.0908","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:30:36Z","timestamp":1773847836000},"page":"e260908","source":"Crossref","is-referenced-by-count":1,"title":["An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins"],"prefix":"10.1001","volume":"9","author":[{"given":"Mark G.","family":"Evans","sequence":"first","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Maney","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Helmstetter","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Johnson","sequence":"additional","affiliation":[{"name":"Departments of Medical Oncology and Otolaryngology, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony N.","family":"Karnezis","sequence":"additional","affiliation":[{"name":"UC Davis Health, Sacramento, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Bales","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Sledge","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Spetzler","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Vanderwalde","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Oberley","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"name":"Departments of Oncology and Medicine, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bryant","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute at Mount Sinai, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Ghani","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"11","key":"zoi260059r1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/cup.12388","article-title":"p40 Is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma.","volume":"41","author":"Alomari","year":"2014","journal-title":"J Cutan Pathol"},{"issue":"1","key":"zoi260059r2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2559.1993.tb01182.x","article-title":"Squamous cell carcinomas. an immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours.","volume":"23","author":"Suo","year":"1993","journal-title":"Histopathology"},{"issue":"3","key":"zoi260059r3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/modpathol.2011.173","article-title":"p40 (?Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.","volume":"25","author":"Bishop","year":"2012","journal-title":"Mod Pathol"},{"issue":"9","key":"zoi260059r4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/PAI.0000000000000943","article-title":"Variations of p40 and p63 immunostains in different grades of esophageal squamous cell carcinoma: a potential diagnostic pitfall.","volume":"29","author":"Chi","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"zoi260059r5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41568-018-0024-5","article-title":"Deciphering the cells of origin of squamous cell carcinomas.","volume":"18","author":"S\u00e1nchez-Dan\u00e9s","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"zoi260059r6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ccell.2016.04.004","article-title":"Squamous cell cancers: a unified perspective on biology and genetics.","volume":"29","author":"Dotto","year":"2016","journal-title":"Cancer Cell"},{"issue":"11","key":"zoi260059r7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.5858\/arpa.2011-0575-OA","article-title":"Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.","volume":"136","author":"Gruver","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"18","key":"zoi260059r9","doi-asserted-by":"publisher","first-page":"25050","DOI":"10.18632\/oncotarget.7732","article-title":"Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization.","volume":"7","author":"Polo","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"zoi260059r11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","article-title":"Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.","volume":"22","author":"Wang","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"zoi260059r12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025331","article-title":"The incidence and prognosis of thymic squamous cell carcinoma: a Surveillance, Epidemiology, and End Results Program population-based study.","volume":"100","author":"Wu","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"zoi260059r13","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae028","article-title":"New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.","volume":"25","author":"Ma","year":"2024","journal-title":"Brief Bioinform"},{"issue":"9","key":"zoi260059r14","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41591-025-03780-x","article-title":"Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection.","volume":"31","author":"Campanella","year":"2025","journal-title":"Nat Med"},{"issue":"509","key":"zoi260059r15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8513","article-title":"Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases.","volume":"11","author":"Jurmeister","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"zoi260059r16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1158\/2767-9764.CRC-25-0171","article-title":"GPSai: a clinically validated AI tool for tissue of origin prediction during routine tumor profiling.","volume":"5","author":"Ghani","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"20","key":"zoi260059r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"zoi260059r19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.18632\/oncotarget.28761","article-title":"Clinical and analytical validation of MI Cancer Seek, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay.","volume":"16","author":"Domenyuk","year":"2025","journal-title":"Oncotarget"},{"issue":"7793","key":"zoi260059r20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer.","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"6","key":"zoi260059r26","doi-asserted-by":"publisher","first-page":"E82","DOI":"10.1002\/hed.25613","article-title":"Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site.","volume":"41","author":"Chan","year":"2019","journal-title":"Head Neck"},{"issue":"11","key":"zoi260059r27","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/s41379-020-0594-0","article-title":"Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma.","volume":"33","author":"Yang","year":"2020","journal-title":"Mod Pathol"},{"issue":"3","key":"zoi260059r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3833","article-title":"Prevalence of UV mutational signatures among cutaneous primary tumors.","volume":"5","author":"Mata","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi260059r29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/cup.14713","article-title":"Use of UV mutational signatures to distinguish between cutaneous and pulmonary primary squamous cell carcinoma.","volume":"53","author":"Ross","year":"2026","journal-title":"J Cutan Pathol"},{"issue":"5","key":"zoi260059r30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3322\/caac.21293","article-title":"Oral cavity and oropharyngeal squamous cell carcinoma\u2013an update.","volume":"65","author":"Chi","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"zoi260059r31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.oraloncology.2008.07.008","article-title":"Oropharyngeal carcinoma in non-smokers and non-drinkers: a role for HPV.","volume":"45","author":"Andrews","year":"2009","journal-title":"Oral Oncol"},{"issue":"1","key":"zoi260059r32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0194599817733677","article-title":"An algorithm to evaluate suspected lung metastases in patients with HPV-associated oropharyngeal cancer.","volume":"158","author":"VanKoevering","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"zoi260059r33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/PAS.0b013e3182395c7b","article-title":"HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.","volume":"36","author":"Bishop","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"zoi260059r34","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1350","article-title":"HPV and lung cancer: a systematic review and meta-analysis.","volume":"4","author":"Karnosky","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"zoi260059r35","doi-asserted-by":"publisher","first-page":"A243","DOI":"10.1093\/ajcp\/142.suppl1.243","article-title":"p40 Does not discriminate urinary bladder urothelial carcinomas with or without squamous differentiation from primary squamous cell carcinomas of lung origin.","volume":"142","author":"Poveda","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"zoi260059r36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/PAI.0000000000000143","article-title":"Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma.","volume":"23","author":"Hoang","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"zoi260059r37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/modpathol.2016.53","article-title":"High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.","volume":"29","author":"Cowan","year":"2016","journal-title":"Mod Pathol"},{"issue":"22","key":"zoi260059r38","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience.","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"zoi260059r39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4103\/ijmpo.ijmpo_148_16","article-title":"Utility of cluster of differentiation 5 and cluster of differentiation 117 immunoprofile in distinguishing thymic carcinoma from pulmonary squamous cell carcinoma: a study on 1800 nonsmall cell lung cancer cases.","volume":"38","author":"Jha","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"1","key":"zoi260059r40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1378\/chest.128.1.140","article-title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.","volume":"128","author":"Nakagawa","year":"2005","journal-title":"Chest"},{"issue":"5","key":"zoi260059r41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/PAI.0b013e318297cdb5","article-title":"Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma.","volume":"22","author":"Asirvatham","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"zoi260059r42","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.21037\/med-21-52","article-title":"Thymic carcinomas vs. lung carcinomas\u2014pathologist\u2019s perspective: extended abstract.","volume":"6","author":"Szolkowska","year":"2022","journal-title":"Mediastinum"},{"issue":"5","key":"zoi260059r43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.20517\/2394-4722.2021.210","article-title":"Molecular pathology of thymoma and thymic carcinoma.","volume":"8","author":"Suster","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"issue":"7","key":"zoi260059r44","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202402602","article-title":"Brd4:Nutm1 fusion gene initiates NUT carcinoma in vivo.","volume":"7","author":"Zheng","year":"2024","journal-title":"Life Sci Alliance"},{"issue":"5748","key":"zoi260059r45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"4","key":"zoi260059r51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41571-025-00986-3","article-title":"Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck.","volume":"22","author":"Luo","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"zoi260059r52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"zoi260059r54","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.7150\/thno.45311","article-title":"Identification of second primary tumors from lung metastases in patients with esophageal squamous cell carcinoma using whole-exome sequencing.","volume":"10","author":"Xue","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"zoi260059r55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12967-022-03362-2","article-title":"A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.","volume":"20","author":"Chen","year":"2022","journal-title":"J Transl Med"},{"issue":"6312","key":"zoi260059r56","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer.","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"key":"zoi260059r8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-031-14402-8_19","volume-title":"Practical Lung Pathology: Frequently Asked Questions","author":"Lerma","year":"2022"},{"key":"zoi260059r10","unstructured":"Hainsworth? JD, Greco? FA. Squamous cell carcinoma of unknown primary. UpToDate. 2023. Accessed January 28, 2026. https:\/\/www.uptodate.com\/contents\/squamous-cell-carcinoma-of-unknown-primary-site"},{"key":"zoi260059r18","unstructured":"The Belmont Report. US Department of Health and Human Services. Accessed January 28, 2026. https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/belmont-report\/index.html"},{"key":"zoi260059r21","unstructured":"Non-small cell lung cancer (version 3.2025). National Comprehensive Cancer Network. Accessed June 27, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"zoi260059r22","unstructured":"Thymomas and thymic carcinomas (version 1.2025). National Comprehensive Cancer Network. Accessed June 27, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thymic.pdf"},{"key":"zoi260059r23","unstructured":"Bladder cancer (version 1.2025). National Comprehensive Cancer Network. Accessed June 27, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"key":"zoi260059r24","unstructured":"Head and neck cancers (version 2.2025). National Comprehensive Cancer Network. Accessed June 27, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf"},{"key":"zoi260059r25","unstructured":"Squamous cell skin cancer (version 2.2025). National Comprehensive Cancer Network. Accessed June 27, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/squamous.pdf"},{"key":"zoi260059r46","unstructured":"Prostate cancer (version 2.2025). National Comprehensive Cancer Network. Accessed September 10, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"zoi260059r47","unstructured":"Cervical cancer (version 4.2025). National Comprehensive Cancer Network. Accessed September 10, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf"},{"key":"zoi260059r48","unstructured":"Anal carcinoma (version 3.2025). National Comprehensive Cancer Network. Accessed September 10, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf"},{"key":"zoi260059r49","unstructured":"Vulvar cancer (version 1.2025). National Comprehensive Cancer Network. Accessed September 10, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vulvar.pdf"},{"key":"zoi260059r50","unstructured":"Penile cancer (version 2.2025). National Comprehensive Cancer Network. Accessed September 10, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf"},{"key":"zoi260059r53","unstructured":"SEER incidence data, November 2024 submission (1975-2022), SEER 21 registries. SEER*Explorer. April 16, 2025. Accessed April 30, 2025. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846635\/evans_2026_oi_260059_1773255253.78623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:30:41Z","timestamp":1773847841000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.0908","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}